Trial ID or NCT#



not recruiting iconNOT RECRUITING


The primary objective of the study is to evaluate 68Ga-DOTA TATE PET/CT for staging and monitoring response to chemotherapy in patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.

Official Title

68Ga DOTA-TATE PET/CT in the Evaluation of Patients With Somatostatin Receptor Positive Tumors

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Andrei Iagaru
Andrei Iagaru
Professor of Radiology (Nuclear Medicine)
Jeffrey Norton, MD
Jeffrey Norton, MD
Surgical oncologist
Robert L. and Mary Ellenburg Professor of Surgery

Contact us to find out if this trial is right for you.


Krithika Rupnarayan
(650) 736-0959